Effects of the PARP Inhibitor Olaparib on the Response of Human Peripheral Blood Leukocytes to Bacterial Challenge or Oxidative Stress

Prior studies demonstrate the activation of poly-(ADP-ribose) polymerase 1 (PARP1) in various pathophysiological conditions, including sepsis. We have assessed the effect of olaparib, a clinically used PARP1 inhibitor, on the responses of human peripheral blood leukocytes (PBMCs) obtained from healt...

Descripción completa

Detalles Bibliográficos
Autores principales: Santos, Sidneia Sousa, Brunialti, Milena Karina Coló, Rodrigues, Larissa de Oliveira Cavalcanti Peres, Liberatore, Ana Maria Alvim, Koh, Ivan Hong Jun, Martins, Vanessa, Soriano, Francisco Garcia, Szabo, Csaba, Salomão, Reinaldo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221060/
https://www.ncbi.nlm.nih.gov/pubmed/35740913
http://dx.doi.org/10.3390/biom12060788

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221060/
https://www.ncbi.nlm.nih.gov/pubmed/35740913
http://dx.doi.org/10.3390/biom12060788

Ejemplares similares